Kamil R. Kranc

4.1k citations

41 papers · 2.1k indexed · 1 hit paper · h-index 20

Co-authors: Sten Eirik W. Jacobsen Simon D. Bamforth Shoumo Bhattacharya José Bragança Anna Katharina Simon Gordana Djordjević Michael Lutteropp Elizabeth J. Soilleux
Topics: Acute Myeloid Leukemia Research (12 papers)Hematopoietic Stem Cell Transplantation (9 papers)Epigenetics and DNA Methylation (7 papers)
Cited by: Hematology Cancer Research Immunology
Journals: Nature Nature Communications Nature Genetics
Partner nations: United Kingdom Germany United States

In The Last Decade

Kamil R. Kranc

40 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance

2011 482 citations Kamil R. Kranc et al. profile →

Peers

Countries citing papers authored by Kamil R. Kranc

Since Specialization

Citations

This map shows the geographic impact of Kamil R. Kranc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kamil R. Kranc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kamil R. Kranc more than expected).

Fields of papers citing papers by Kamil R. Kranc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kamil R. Kranc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kamil R. Kranc. The network helps show where Kamil R. Kranc may publish in the future.

Co-authorship network of co-authors of Kamil R. Kranc

This figure shows the co-authorship network connecting the top 25 collaborators of Kamil R. Kranc. A scholar is included among the top collaborators of Kamil R. Kranc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kamil R. Kranc. Kamil R. Kranc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impaired DNA damage responses and inflammatory signaling underpin hematopoietic stem cell defects in Gata2 haploinsufficiency 2025 ·Stem Cell Reports ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Hannah Lawson,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Peter Giles,Alex Tonks,Ashleigh S. Boyd,Kamil R. Kranc,Neil P. Rodrigues	0
2	Dissecting infant leukemia developmental origins with a hemogenic gastruloid model 2025 ·eLife ·(unknown),Chun-Wai Suen,(unknown),Fabio Pastorino,(unknown),(unknown),(unknown),Susanne van den Brink,(unknown),(unknown),G. Ionescu,Joana Cerveira,Kamil R. Kranc,Víctor Hernández-Hernández,Mirco Ponzoni,Anna Bigas,Jordi García‐Ojalvo,Alfonso Martínez Arias,Cristina Pina	1
3	Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient‐derived xenografts 2024 ·HemaSphere ·Vilma Dembitz,(unknown),Joana Campos,(unknown),Hannah Lawson,Kamil R. Kranc,Paolo Gallipoli	2
4	Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death 2023 ·Nature Communications ·(unknown),(unknown),George Giotopoulos,Pedro Madrigal,(unknown),Céline Philippe,Vilma Dembitz,(unknown),(unknown),Louie N. van de Lagemaat,Christopher Mapperley,(unknown),Jochen H.M. Prehn,Konstantinos Tzelepis,Kevin Rouault‐Pierre,George S. Vassiliou,Kamil R. Kranc,G. Vignir Helgason,Brian J.P. Huntly,Paolo Gallipoli	14
5	Haematopoietic stem cell health in sickle cell disease and its implications for stem cell therapies and secondary haematological disorders 2023 ·Blood Reviews ·(unknown),Kamil R. Kranc,Miguel Ganuza,Paul Telfer	3
6	m6A RNA modifications: Key regulators of normal and malignant hematopoiesis 2022 ·Experimental Hematology ·Pia Sommerkamp,Jessie Brown,Myriam Haltalli,François Mercier,Ly Vu,Kamil R. Kranc	1
7	A functional screen of RNA binding proteins identifies genes that promote or limit the accumulation of CD138+ plasma cells 2022 ·eLife ·David J. Turner,Alexander Saveliev,Fiamma Salerno,Louise S. Matheson,Michael Screen,Hannah Lawson,(unknown),Kamil R. Kranc,Martin Turner	12
8	NANOS2 is a sequence-specific mRNA-binding protein that promotes transcript degradation in spermatogonial stem cells 2021 ·iScience ·(unknown),Tomasz W. Turowski,Louie N. van de Lagemaat,Ivayla Ivanova,Andrea Tavosanis,Christian Much,Tania Auchynnikava,Lina Vasiliauskaitė,Marcos Morgan,Juri Rappsilber,Robin C. Allshire,Kamil R. Kranc,David Tollervey,Dónal O’Carroll	12
9	CITED2 coordinates key hematopoietic regulatory pathways to maintain the HSC pool in both steady-state hematopoiesis and transplantation 2021 ·Stem Cell Reports ·Hannah Lawson,Louie N. van de Lagemaat,Melania Barile,Andrea Tavosanis,(unknown),Arnaud Villacreces,(unknown),Christopher Mapperley,(unknown),(unknown),Catarina Sepúlveda,Lewis Allen,Joana Campos,Kirsteen J. Campbell,Dónal O’Carroll,Berthold Göttgens,Suzanne Cory,Neil P. Rodrigues,Amélie V. Guitart,Kamil R. Kranc	10
10	Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms 2019 ·Leukemia ·Julian Baumeister,Nicolas Chatain,(unknown),Tiago Maié,Ivan G. Costa,Bernd Denecke,Lijuan Han,(unknown),Stephanie Sontag,Kristin Seré,Klaus Strathmann,Martin Zenke,Andreas Schuppert,Tim H. Brümmendorf,Kamil R. Kranc,Steffen Koschmieder,Deniz Gezer	41
11	Machine Learning Enables Live Label-Free Phenotypic Screening in Three Dimensions 2018 ·Assay and Drug Development Technologies ·Eoghan O’Duibhir,J Paris,Hannah Lawson,Catarina Sepúlveda,(unknown),Neil O. Carragher,Kamil R. Kranc	8
12	hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival 2018 ·Blood ·Francesca Pellicano,(unknown),Lisa Hopcroft,(unknown),(unknown),Mary T. Scott,(unknown),Amy Sinclair,Sheela A. Abraham,Alan Hair,G. Vignir Helgason,Mark Aspinall-O’Dea,Ravi Bhatia,Gustavo Leone,Kamil R. Kranc,Anthony D. Whetton,Tessa L. Holyoake	33
13	Condensin II mutation causes T-cell lymphoma through tissue-specific genome instability 2016 ·Genes & Development ·(unknown),Gillian C.A. Taylor,Dinesh C. Soares,Shelagh Boyle,Daoud Sie,David Read,(unknown),Milica Vukovic,Núria Tarrats,David Jamieson,Kirsteen J. Campbell,Karen Blyth,Juan Carlos Acosta,Bauke Ylstra,Mark J. Arends,Kamil R. Kranc,Andrew P. Jackson,Wendy A. Bickmore,Andrew J. Wood	33
14	The role of 2-oxoglutarate dependent dioxygenases in normal haematopoiesis and acute myeloid leukemia 2015 ·Haematologica ·(unknown),Amélie V. Guitart,Milica Vukovic,(unknown),(unknown),(unknown),Peter J. Ratcliffe,Kamil R. Kranc	2
15	Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism 2014 ·PubMed ·Patrick J. Pollard,Ming Yang,(unknown),Tomoyoshi Soga,Kamil R. Kranc	48
16	T Cell-Mediated Autoimmune Disease Due to Low-Affinity Crossreactivity to Common Microbial Peptides 2009 ·Immunity ·Maria Harkiolaki,(unknown),Pia Svendsen,Jon Waarst Gregersen,Lise Torp Jensen,Róisín M. McMahon,Manuel A. Friese,Gijs van Boxel,Ruth Etzensperger,John S. Tzartos,Kamil R. Kranc,Sarah Sainsbury,Karl Harlos,Elizabeth Mellins,Jackie Palace,Margaret M. Esiri,P. Anton van der Merwe,E. Yvonne Jones,Lars Fugger	2
17	T Cell-Mediated Autoimmune Disease Due to Low-Affinity Crossreactivity to Common Microbial Peptides (DOI:10.1016/j.immuni.2009.01.009) 2009 ·Immunity ·Maria Harkiolaki,(unknown),P. Svendsen,Jon Waarst Gregersen,(unknown),Róisín M. McMahon,Michael Friese,Gijs van Boxel,Ruth Etzensperger,John S. Tzartos,Kamil R. Kranc,Sarah Sainsbury,Karl Harlos,(unknown),Jacqueline Palace,M M Esiri,P. Anton van der Merwe,E. Yvonne Jones,Lars Fugger	5
18	Functional epistasis on a common MHC haplotype associated with multiple sclerosis 2006 ·Nature ·Jon Waarst Gregersen,Kamil R. Kranc,Xiayi Ke,Pia Svendsen,Lars Siim Madsen,Allan Randrup Thomsen,Lon R. Cardon,John I. Bell,Lars Fugger	154
19	Control of autoimmunity by ?epitope theft? 2004 ·Trends in Molecular Medicine ·Kamil R. Kranc,Andrew J. Taylor,Nicholas Willcox,Lars Fugger	2
20	Oxidative degradation of bilirubin produces vasoactive compounds 2000 ·European Journal of Biochemistry ·Kamil R. Kranc,Gail J. Pyne,Limei Tao,Timothy D. W. Claridge,David A. Harris,Thomas A.D. Cadoux-Hudson,Jonathan J. Turnbull,Christopher J. Schofield,Joseph F. Clark	77

About Kamil R. Kranc

Kamil R. Kranc is a scholar working on Hematology, Genetics and Aging, having authored 41 papers that have together received 2.1k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (12 papers), Hematopoietic Stem Cell Transplantation (9 papers) and Epigenetics and DNA Methylation (7 papers). The work is most often cited by research in Hematology (479 citations), Cancer Research (388 citations) and Immunology (446 citations). Kamil R. Kranc has collaborated with scholars based in United Kingdom, Germany and United States. Frequent co-authors include Sten Eirik W. Jacobsen, Simon D. Bamforth, Shoumo Bhattacharya, José Bragança, Anna Katharina Simon, Gordana Djordjević, Michael Lutteropp, Elizabeth J. Soilleux, Amanda J. Stranks and Samantha J.L. Knight. Their work appears in journals such as Nature, Nature Communications and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact